Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A decade of clinical development of PARP inhibitors in perspective
Joaquı́n Mateo, Christopher J. Lord, Violeta Serra, et al.
Annals of Oncology (2019) Vol. 30, Iss. 9, pp. 1437-1447
Open Access | Times Cited: 568

Showing 1-25 of 568 citing articles:

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1164
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Ruixue Huang, Ping‐Kun Zhou
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 810
Targeting metastatic cancer
Karuna Ganesh, Joan Massagué
Nature Medicine (2021) Vol. 27, Iss. 1, pp. 34-44
Open Access | Times Cited: 748
PARP and PARG inhibitors in cancer treatment
Dea Slade
Genes & Development (2020) Vol. 34, Iss. 5-6, pp. 360-394
Open Access | Times Cited: 525
Adaptive mutability of colorectal cancers in response to targeted therapies
Mariangela Russo, Giovanni Crisafulli, Alberto Sogari, et al.
Science (2019) Vol. 366, Iss. 6472, pp. 1473-1480
Open Access | Times Cited: 361
Targeting mutant p53 for cancer therapy: direct and indirect strategies
Jiahao Hu, Jiasheng Cao, Win Topatana, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 361
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 12, pp. 773-791
Closed Access | Times Cited: 359
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Laura Cortesi, Hope S. Rugo, Christian Jackisch
Targeted Oncology (2021) Vol. 16, Iss. 3, pp. 255-282
Open Access | Times Cited: 302
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
Pierre‐Marie Morice, Alexandra Léary, Charles Dolladille, et al.
The Lancet Haematology (2020) Vol. 8, Iss. 2, pp. e122-e134
Closed Access | Times Cited: 199
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
Mihaela Aldea, Fabrice André, Aurélien Marabelle, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 874-899
Open Access | Times Cited: 197
Hereditary breast cancer
Raquel Andrés Conejero, Rodrigo Lastra del Prado, María Zurera Berjaga, et al.
Revisiones en Cáncer (2022)
Open Access | Times Cited: 193
Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants
Shuai Li, Valentina Silvestri, Goska Leslie, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 14, pp. 1529-1541
Open Access | Times Cited: 184
Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases
Simonetta Pazzaglia, Claudio Pioli
Cells (2019) Vol. 9, Iss. 1, pp. 41-41
Open Access | Times Cited: 172
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
Hans Petter Eikesdal, Synnøve Yndestad, Ahmed El‐Zawahry, et al.
Annals of Oncology (2020) Vol. 32, Iss. 2, pp. 240-249
Open Access | Times Cited: 165
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
Ethan S. Sokol, Dean C. Pavlick, Hossein Khiabanian, et al.
JCO Precision Oncology (2020), Iss. 4, pp. 442-465
Open Access | Times Cited: 139
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 136
The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling
Adrienn Sipos, Gyula Ujlaki, Edit Mikó, et al.
Molecular Medicine (2021) Vol. 27, Iss. 1
Open Access | Times Cited: 104
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Giuditta Illuzzi, Anna D. Staniszewska, Sonja J. Gill, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 21, pp. 4724-4736
Open Access | Times Cited: 96
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
Joshua J. Gruber, Anosheh Afghahi, Kirsten M. Timms, et al.
Nature Cancer (2022) Vol. 3, Iss. 10, pp. 1181-1191
Open Access | Times Cited: 83
Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer
Nitasha Gupta, Tzu‐Ting Huang, Sachi Horibata, et al.
Pharmacological Research (2022) Vol. 178, pp. 106162-106162
Open Access | Times Cited: 78
PARP inhibitors: enhancing efficacy through rational combinations
Deepak Bhamidipati, Jaime Haro-Silerio, Timothy A. Yap, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 6, pp. 904-916
Open Access | Times Cited: 73
BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
Xiaoyu Fu, Wei Phin Tan, Qibin Song, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 71
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 51
A review: FDA-approved fluorine-containing small molecules from 2015 to 2022
Negar Sheikhi, Maryam Bahraminejad, Mina Saeedi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115758-115758
Closed Access | Times Cited: 47
Development of PARP inhibitors in advanced prostate cancer
María T. Bourlon, Paola Valdez, Elena Castro
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top